

SUPPLEMENTARY TABLE

Supplementary Table 1. Association between BTK expression and clinicopathologic parameters.

Characteristics	Total (n = 32)	BTK expression		χ^2	P value
		High (n = 19)	Low (n = 13)		
Gender				0.076	0.545
Male	23 (72%)	14 (73.7%)	9 (69.2%)		
Female	9 (28%)	5 (26.3)	4 (30.8%)		
Age				1.943	0.153
<65	20 (63%)	10 (52.6%)	10 (76.9%)		
≥65	12 (37%)	9 (47.4%)	3 (23.1%)		
ECOG score				4.055	0.058
0–1	27 (84%)	14 (73.7%)	13 (100%)		
2–4	5 (16%)	5 (26.3%)	0 (0%)		
B symptoms				0.162	0.487
No	21 (66%)	13 (68.4%)	8 (61.5%)		
Yes	11 (34%)	6 (31.6%)	5 (38.5%)		
Stage				4.838	0.051
I-II	3 (9%)	0 (0%)	3 (23.1%)		
III-IV	29 (91%)	19 (100%)	10 (76.9%)		
BM involvement				2.496	0.114
No	12 (37%)	5 (26.3%)	7 (53.8%)		
Yes	20 (63%)	14 (73.7%)	6 (46.2%)		
WBC/mm				0.173	0.327
<10,000	21 (66%)	12 (63.2%)	9 (69.2%)		
≥10,000	11 (34%)	7 (36.8%)	4 (30.8%)		
β2-MG				0.275	0.521
≤3 mg/L	18 (56%)	8 (47%)	10 (67%)		
>3 mg/L	14 (44%)	9 (53%)	5 (33%)		
LDH(IU/L)				0.13	0.5
<250	16 (50%)	9 (47.4%)	7 (53.8%)		
≥250	16 (50%)	10 (52.6%)	6 (46.2%)		
Ki-67				5.783	0.019*
≤30%	19 (59%)	8 (42.1%)	11 (84.6%)		
>30%	13 (41%)	11 (57.9%)	2 (15.4%)		
MIPI score				4.522	0.038*
Low-Middle risk (<6)	23 (72%)	11 (57.9%)	12 (92.3%)		
Middle-High risk (≥6)	9 (28%)	8 (42.1%)	1 (7.7%)		